The purpose of this study was to evaluate the outcome after RaCl2) treatment of patients with skeletal metastases of castration resistant prostate cancer using whole-body RaCl2, after the first cycle and after the sixth cycle. The skeletal metastases were analyzed quantitatively using modified PET response evaluation PERCIST criteria. The patients were also analyzed for S-PSA. All ten patients responded in [ 
Introduction
Prostate cancer is the most common cancer in Europe and 10%-20% of patients present with advanced or metastatic disease with associated symptomatic bone metastases [1] . Bone is the most frequent metastatic site in prostate cancer, with approximately 90% of patients with metastatic castration resistant prostate cancer (mCRPC) having radiological evidence of bone metastases [2] . Bone metastases profoundly affect an individual's quality of life, increase the risk of bone marrow failure [3] and skeletal-related events (SREs) such as pathological fractures and spinal cord compression [4] , and significantly reduce life expectancy [5, 6] . The main cause of disability and death among those with mCRPC is bone metastases.
According to EANM guidelines, patients considered for therapy with beta-emitting radiopharmaceuticals such as 89 Sr-Cl, 153 Sm-EDTMP or 186 Re-HEDP therapy had to fail in conventional analgesics and anti-tumor therapy, chemotherapy or hormone therapy. Pain had to be severe enough to limit normal activities and/or require regular analgesics, and patients had to undergo recent (within 8 weeks or less) bone scintigraphy documenting increased osteoblastic activity at painful sites. These radionuclide treatments are palliative, where 60%-80% of patients benefit from the treatment and they do not cure metastatic cancer [7, 8] . All of these agents have demonstrated improved overall survival in retrospective controlled studies [9] [10] [11] , but there are not yet randomized controlled studies which support these findings, only studies which do not improve survival [12] . In 2010's, the bone-seeking radiopharmaceutical, radium-223 dichloride ( 223 RaCl2), was introduced into clinical practice.
223
RaCl2 is indicated for the treatment of patients with mCRPC and symptomatic bone metastases, offering overall survival benefits comparable to the other new treatment options available [13] [14] [15] . The availability of 223 RaCl2 has generated considerable interest amongst the nuclear medicine community, and in many centers around the world nuclear medicine physicians have joined the multidisciplinary treatment team involved in the management of patients with mCRPC. This
RaCl2 is an alpha-emitting bone targeting agent, which has favorable pharmacokinetic and pharmacodynamic characteristics: at 10 min 12%, at 1 h 6% and at 24 h <1% of the injected activity is in the blood and the skeletal uptake is 44%-77% at 4 h. Fecal excretion is the major elimination route, but additionally 5% is excreted in the urinary tract [15, 16] . In regards to diagnostic imaging of these patients, the Society for Nuclear Medicine published guidelines for [ 18 F]-NaF PET/CT bone scans [17] . Bone uptake of 18 F-NaF reflects bone remodeling, and it is part of the mineralization of bone matrix. F-Choline PET/CT had similar diagnostic accuracy at staging for patients with prostate cancer but 18 F-Choline has higher specificity at restaging for recurrence [28] .
In this article, the outcome of
RaCl2 treatment was analyzed using [
18 F]-NaF-PET.
Methods and Patients
Patients: Prostate cancers were diagnosed between 2001 and 2013. In this retrospective one institute analysis we included all those patients who had received at least 6 cycles of 223 RaCl2 therapy. Men's ages ranged from 49 to 83 years; Gleason scores were 6-10; initial PSA values varied from 5.5 to 15,500 μg/L, and all patients had T3-T4 disease. All the patients had skeletal metastases, and two of them additionally had visceral metastases. The radiological TNM staging before Table 1 . This work is a retrospective treatment analysis of our ten first Ra-223 patients followed with [ 18 F]-NaF PET/CT imagings. This retrospective analysis was performed, according to the principles of the Declaration of Helsinki and our patient database was approved by the Finnish authority for the protection of privacy and personal data. All patients gave a written informed consent for the use their data.
Imaging PET/CT protocol: Imaging was done on Siemens Biograph PET Scanner, combined with low-dose CT. The injected activity dose of [ ]-NaF PET/CT imaging was applied before Ra-223 therapy in all patients, in 6 patients after the 1st cycle and in all patients after the last 6th cycle ( Table 2 ). In one patient (no. 6) there was a production failure of 223 RaCl2 and the interval between the 1st and 2nd cycle was 10 weeks instead of normal 4 weeks. He was imaged after the 2nd cycle, and received a total of 7 cycles. The [ 
Alpha-therapy:
223 RaCl2 (Xofigo ® ) was acquired from Bayer Healthcare AG (Berlin, Germany), each single-use vial contained 6 mL of solution at a concentration of 1000 kBq/mL (27 μCi/mL) and a total radioactivity of 6 MBq/vial (162 μCi/vial) at the reference date [29] . The used activity dose of 223 RaCl2 is 50 kBq/kg body weight (1.35 μCi/kg) given at 4-weekly intervals for six cycles, the cumulative activities are listed in Table 2 . The volume administered was calculated using the patient's body weight (kg), the dosage level (50 kBq/kg body weight), the radioactivity concentration of the product at the reference date, and the decay correction factor provided with each vial.
Prior to the first dose, patients were analyzed for a full blood count (FBC) to assess bone marrow function. Treatment was given if: haemoglobin level >10 g/dL, absolute neutrophil count (ANC) ≥1.5 × 10 Image analysis: Lesions were considered abnormal when focal tracer accumulation was greater than background activity, usually if the SUV values were higher than 10.
Interpretation of bone lesions (benign or malignant) depended on anatomical localization; and the five regions: skull, vertebral column, thoracic girdle, pelvic girdle and extremities were estimated quantitatively using modified PERCIST criteria for NaF. In the classic PERCIST analysis, the skeleton is considered as organ, and a maximum of two lesions per organ are taken into account out of the total sum of five lesions. Therefore, here two highest SUVmax values of skeletal uptakes from two regions were summed. The results were compared with those of base line, the change of 6% were considered significant as in conventional PERCIST consisting of 5 lesions, where 15% change is considered significant which is analogous to PERCIST criteria for early response [30] . 
Statistical analysis:
The acquired results were expressed as the mean ± SEM for each index. Comparison of data among various groups was performed with Student's unpaired t-test. A p < 0.05 was considered statistically significant. Correlation between groups was calculated using linear regression analysis.
Results
The summary of imaging results is presented in Table 2 . All patients responded to their treatment according to the [ ]-NaF-PET activity due to the Ra-223 treatment was seen after 1st cycle (+6.3% change), whereas after 6 cycles a dramatic response was seen (−63.5% change). (IV-14) , where the changes in the bone marrow had dramatically disappeared. However, NaF-PET on the following day (IV-14) demonstrated a widespread active cortical bone disease. This did not respond to the treatment after 1st cycle (+6.2% change, V-14), but after 6 cycles a response was seen (−6.2% change, IX-14). Demonstrates an old patient (83 years) with Gleason score 6. The NaF-PET before the Ra-223 treatment 6 cycles is shown (II-15), but no essential response to the treatment after 1st cycle (+6.3% change, III-15) was seen, whereas after 6 cycles a dramatic response was seen (−63.5% change, VIII-15). Many of the lesions have disappeared, especially in the thoracic girdle.
Discussion
Our patients with active mCRPC all responded to their treatments, because quantitatively there was a significant decrease in [ RaCl2 as compared to the baseline measurements. The quantitative decrement varied from −6.9% to −68.4%. The change can be visually seen in Figure 5 (quantitatively −63.5%), but no so easily in Figures 2-4 (quantitatively −6.9% to 13.0%). Therefore, quantification is important in widespread, i.e. more than 10% of skeleton, metastatic bone disease. According to the S-PSA measurements all patients except one (patient no. 1) showed some response in an active aggressive (T3-T4) widespread skeletal disease.
There are now multiple new therapies providing options for the treatment of patients having metastatic castration-resistant prostate cancer (mCRPC). For these patients, therapies were just very recently exceptionally ineffective and extremely limited to the use of docetaxel. These new therapies include androgen synthesis inhibitor (abiraterone) [32] , androgen receptor signaling inhibitor (enzalutamide) [33] , radionuclide therapy (radium-223) [34] [35] [36] [37] and cabazitaxel chemotherapy [38] .
Radium-223 was the first bone-seeking radionuclide that is reported to increase overall survival, and quality of life by providing pain relief in their late stage disease from symptomatic skeletal events (SSEs) such as bone pain, pathological fractures, or spinal cord compression seen in up to 90% of mCRPC patients. This new drug, radium-223-dichloride ( Our patients with active mCRPC all responded to the given therapies. The common denominator was that they all received multimodality treatments with response. All of them received radium-223-dichloride ( 223 RaCl2) plus denosumab, but otherwise this group of 10 patients was very heterogeneous. This is usually the case in retrospective analysis describing the clinical practice, when it comes to their demographics and previous and concomitant therapies (Tables 1 and 2 ).
In addition to the overall survival and QOL benefits, all the secondary endpoints were also met in the Phase 3 ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) registration trial [30] [31] [32] [33] , which included the delay in time to first skeletal-related events: first events occurred in 13.6 months in the RaCl2 is a bone targeting treatment, its response using bone targeting imaging has not yet been assessed in the literature. There is evidence that NaF-PET can be used as a prognostic factor of the outcome of Ra-223 treatment [39] . They demonstrated that skeletal metastatic burden on baseline will reflect on the outcome of 223 RaCl2 treatment and appearance of skeletal related events. In the PERCIST criteria [30] early minor response is recorded, if there is a 15% decrease in a total sum of 5 lesions; however, a maximum of two lesions can be taken from the same organ. In our modified criteria we therefore selected just the two lesions to represent the whole skeleton. If we use the 30% criteria for partial response as in PERCIST [30] , the limit would be 12%, meaning that only 5 of our 10 patients demonstrated response. In the MD Anderson Cancer Center study [40] , also the total skeletal volume was analyzed based on SUV-threshold of 10. However, this cannot be applied in the clinical routine, and it does not exclude heterogeneity in the metastatic distribution. It is a challenge to identify the best possible way of interpreting total malignant activity in the skeleton. In this work we wanted to present a simple method for routinely analyzing the overall skeletal situation, and it seems, at least preliminarily, that we have been successful. The threshold has to be settled in a larger patient population.
All our patients were diagnosed with multiple PET tracers which all can be used for assessment of skeletal metastatic distribution. It is obvious, e.g., patient no. 2 who was scanned with [ ]-NaF uptake after 6 cycles, however, was significantly lower in all 10 patients as compared to the baseline. Therefore, we postulate that skeletal response to therapies can be assessed with [ 18 F]-NaF. There was also a change in PSA (Figure 1 ). Response to the therapies can be due to combined effect of abiraterone, enzalutamide or denosumab and Ra-223 alone. Ra-223 and denosumab were the only common regimens in all these therapies. On the other hand Ra-223 can be combined with other therapies with success even though the mechanisms and combinations have to be studied carefully in order to understand the causality.
Conclusion
Our results suggest that 
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